Market Place
Sourcing Support
NurExone Secures $3.18M Via Accelerated Warrant Exercises
12 Nov 2025 //
GLOBENEWSWIRE
NurExone`s Exosomes Outperform Industry Standard in Healing
08 Aug 2025 //
GLOBENEWSWIRE
NurExone: Preclinical Success in Optic Nerve Damage Vision Recovery
06 Dec 2024 //
GLOBENEWSWIRE
NurExone Biologic Presents At Industry-Leading Conferences
12 Sep 2024 //
GLOBENEWSWIRE
NurExone Shows Extended Therapeutic Window For ExoPTEN In SCI Study
06 Sep 2024 //
GLOBENEWSWIRE
NurExone Reports Q2 2024 Results And Provides Corporate Update
28 Aug 2024 //
GLOBENEWSWIRE
NurExone Biologic To Present ExoPTEN Therapy At September Conferences
23 Aug 2024 //
GLOBENEWSWIRE
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
29 Jul 2024 //
GLOBENEWSWIRE
NurExone Reports Promising Results For Glaucoma Treatment
17 Jul 2024 //
GLOBENEWSWIRE
Updates from NurExone: Growth Conference Presentation and Website Relaunch
05 Jul 2024 //
GLOBENEWSWIRE
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 Jun 2024 //
GLOBENEWSWIRE
NurExone Announces Expansion of ExoPTEN Patent Coverage with NOA
11 Jun 2024 //
GLOBENEWSWIRE
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
04 Jun 2024 //
GLOBENEWSWIRE
NurExone Q1 2024 Results, Advancing FDA Human Trial Plans
29 May 2024 //
GLOBENEWSWIRE
NurExone Welcomes Dr Ram Petter For Strategic Collaborations
17 May 2024 //
GLOBENEWSWIRE
NurExone Expands to US Markets with OTCQB, DTC Status
25 Apr 2024 //
GLOBENEWSWIRE
NurExone Presents Spinal Cord Injury Therapy At EU Exosome Conference
19 Apr 2024 //
GLOBENEWSWIRE
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 FR
02 Apr 2024 //
GLOBENEWSWIRE
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
27 Mar 2024 //
GLOBENEWSWIRE
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement
22 Mar 2024 //
GLOBENEWSWIRE
Submission of OTCQB Listing Application to Initiate US financial presence
15 Mar 2024 //
GLOBENEWSWIRE
NurExone establishing Research and Development Facility in Haifa, Israel
08 Mar 2024 //
GLOBENEWSWIRE
NurExone™s Intellectual Property Portfolio Expands
20 Feb 2024 //
GLOBENEWSWIRE
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research
17 Jan 2024 //
GLOBENEWSWIRE
NurExone Announces Closing of a Private Placement for Gross Proceeds of CAD$2M
05 Jan 2024 //
GLOBENEWSWIRE
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio
29 Nov 2023 //
GLOBENEWSWIRE
NurExone Reports Third Quarter 2023 Financial Results
24 Nov 2023 //
GLOBENEWSWIRE
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board
19 Oct 2023 //
GLOBENEWSWIRE
NurExone Secures Eureka Grant to Expand to Chronic Spinal Cord Injury Therapy
11 Oct 2023 //
GLOBENEWSWIRE
NurExone Appoints Dr. Reuter Investor Relations in Europe
28 Sep 2023 //
GLOBENEWSWIRE
NurExone Announces Closing of Second Tranche of Private Placement
06 Sep 2023 //
GLOBENEWSWIRE
NurExone Announces Private Placement
09 Aug 2023 //
GLOBENEWSWIRE
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality
20 Jul 2023 //
GLOBENEWSWIRE
Regeneration & Reinnervation of Spinal Cord in Rats Treated with NurExone
22 Jun 2023 //
GLOBENEWSWIRE
NurExone and Particle Metrix Announce Collaboration in Vesicles Analysis
01 Jun 2023 //
GLOBENEWSWIRE
NurExone Reports 1Q 2023 FYR and Provides Corporate Update
24 May 2023 //
GLOBENEWSWIRE
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN
16 May 2023 //
GLOBENEWSWIRE
NurExone Announces Q4 and Reports Full 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
